Market Overview 2025-2033
The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is growing due to increasing legalization, rising medical applications, and expanding research initiatives. Innovations in product development, regulatory support, and patient demand are driving expansion, making it a dynamic and evolving industry.
Key Market Highlights:
✔️ Rapid market growth driven by increasing legalization and acceptance of cannabis for medical use
✔️ Rising demand for cannabis-based treatments in pain management, neurology, and oncology
✔️ Expanding research and investment in pharmaceutical-grade cannabis production and innovation
Request for a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample
Europe Medical Cannabis Market Trends and Drivers:
The Europe medical cannabis market is experiencing rapid growth, driven by evolving regulations and increased medical acceptance. Countries such as Germany, the UK, and Portugal have eased restrictions, making it simpler for doctors to prescribe medical cannabis. In 2024, Germany revised its narcotics laws, significantly expanding patient eligibility. Physicians can now prescribe cannabis for conditions like chronic pain, multiple sclerosis, and chemotherapy-induced nausea without requiring prior approval.
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) streamlined the approval process for cannabis-based medicinal products (CBMPs) in early 2024, leading to a 35% year-on-year increase in patient registrations. These regulatory reforms are helping reduce stigma, allowing pharmacies to stock CBMPs more easily and empowering healthcare providers to incorporate them into treatment plans. However, progress remains uneven across the continent. Southern and Eastern European countries continue to face hurdles due to conservative policy environments, creating a fragmented market landscape.
Chronic pain remains the primary driver of demand for medical cannabis, as patients and doctors seek safer alternatives to opioids amid Europe’s ongoing public health challenges. A 2024 report from the European Pain Federation revealed that 22% of chronic pain patients now use cannabis-based therapies—up from 12% in 2022—highlighting growing physician support. Germany and the Netherlands are leading the way, with health insurers covering CBMPs for conditions like fibromyalgia and neuropathic pain.
The continent’s aging population—where over 20% are aged 65 and older—is further fueling demand. Clinical trials in France and Spain in 2024 reported a 40% reduction in opioid use among patients treated with THC-CBD formulations. In response, hospitals are adopting cannabis-based pain management protocols to promote safer, more effective care.
Meanwhile, innovation and vertical integration are transforming Europe’s medical cannabis supply chain. Licensed producers such as Aurora Cannabis and Tilray are investing heavily in automated indoor farms in Denmark and Portugal. These facilities use AI-driven climate control systems to enhance cannabinoid yields and reduce production costs by 25%—enabling competitive pricing for high-THC strains aimed at treating neurological conditions.
Product development is also accelerating. Pharmacies now offer advanced cannabis delivery formats such as sublingual strips, nano-emulsified oils, and low-dose transdermal patches, catering to precise medical dosing requirements. The EU’s updated Novel Food Regulation (late 2024) has sparked further R&D activity, offering clearer guidelines for cannabinoid-infused edibles and beverages. This has attracted interest from beverage giants and wellness brands looking to enter a market projected to reach €3.2 billion by 2026.
Consolidation and cross-border collaboration are becoming hallmarks of the European medical cannabis industry. Multinational pharmaceutical companies are acquiring local cultivators to secure supply chains, as seen with Jazz Pharmaceuticals’ 2024 majority stake in Germany’s Cannamedical. At the same time, digital health platforms like HelloMD Europe are expanding access through telemedicine, helping patients in remote regions connect with cannabis-specialized physicians.
Partnerships between academia and industry are also thriving. According to a noteworthy 2024 study from the University of Amsterdam, terpene combinations can strengthen the anti-inflammatory effects of CBD, opening the door for novel therapeutic formulations. However, there are still issues, such as uneven compensation guidelines and disparate requirements for product quality.
The European Cannabis Council started a project in 2024 to provide uniform testing procedures and standardized THC labeling within the EU in order to address these problems. The market is expected to increase steadily as a result of more than 1.2 million patient registrations and mounting clinical evidence in favor of medical cannabis. But in order to realize its full potential, regulatory harmonization must be achieved.
Europe Medical Cannabis Market Segmentation:
The report segments the market based on product type, distribution channel, and region:
Study Period:
Base Year: 2024
Historical Year: 2019-2024
Forecast Year: 2025-2033
Breakup by Species:
- Indica
- Sativa
- Hybrid
Breakup by Derivative:
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Breakup by Application:
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
Breakup by End Use:
- Pharmaceutical Industry
- Research and Development Centers
- Others
Breakup by Route of Administration:
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
Breakup by Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Competitive Landscape:
The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145